全文获取类型
收费全文 | 170篇 |
免费 | 6篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 34篇 |
妇产科学 | 3篇 |
基础医学 | 8篇 |
口腔科学 | 5篇 |
临床医学 | 23篇 |
内科学 | 23篇 |
皮肤病学 | 4篇 |
神经病学 | 4篇 |
特种医学 | 46篇 |
外科学 | 3篇 |
综合类 | 1篇 |
预防医学 | 13篇 |
眼科学 | 4篇 |
药学 | 8篇 |
肿瘤学 | 4篇 |
出版年
2021年 | 1篇 |
2019年 | 2篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 4篇 |
2014年 | 5篇 |
2013年 | 3篇 |
2012年 | 1篇 |
2011年 | 2篇 |
2010年 | 8篇 |
2009年 | 8篇 |
2008年 | 6篇 |
2007年 | 10篇 |
2006年 | 1篇 |
2004年 | 1篇 |
2003年 | 2篇 |
2002年 | 1篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1999年 | 6篇 |
1998年 | 16篇 |
1997年 | 13篇 |
1996年 | 14篇 |
1995年 | 8篇 |
1994年 | 5篇 |
1993年 | 8篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1985年 | 7篇 |
1984年 | 5篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 4篇 |
1978年 | 1篇 |
1977年 | 6篇 |
1976年 | 6篇 |
1975年 | 2篇 |
排序方式: 共有183条查询结果,搜索用时 15 毫秒
11.
12.
Pneumocystis carinii pneumonia studied by gallium-67 scanning 总被引:1,自引:0,他引:1
The validity and reliability of gallium-67 (Ga-67) scanning for diagnosis and follow-up of Pneumocystis carinii pneumonia (PCP) were assessed in 34 patients thought to have pulmonary complications of acquired immunodeficiency syndrome (AIDS). Overall sensitivity was 94% and specificity 74%. Among patients with normal or equivocal chest radiographs at the time of admission, sensitivity was 86% and specificity 85%. The authors consider Ga-67 scanning a valid and reliable adjunct in the diagnosis of PCP in AIDS patients with respiratory symptoms when the chest radiograph is normal or equivocal. 相似文献
13.
Magill HL; Clarke EA; Fitch SJ; Boulden TF; Ramirez R; Siegle RL; Somes GW 《Radiology》1986,161(3):625-630
A multicenter clinical study was conducted using iohexol, a second-generation nonionic contrast medium, for excretory urography performed in 130 children. Doses of iohexol (300 mg iodine/ml) ranged between 150 and 660 mgI/kg (0.5 and 2.2 ml/kg). Iohexol was tolerated well, and no significant adverse reactions occurred. Sixty-five iohexol urograms were evaluated to determine the minimum dose for adequate visualization of the kidneys and collecting systems. A dose greater than 300 mgI/kg (1.0 ml/kg) always resulted in a urogram of diagnostic quality, while visualization was insufficient for diagnosis in 10% of studies done with doses of 150-300 mgI/kg (0.5-1.0 ml/kg). Another 65 iohexol urograms were compared in a blinded manner with a similar number of studies performed using iothalamate meglumine at comparable iodine concentration and dose. Visualization of calyces and pelvoinfundibular structures achieved with iohexol was rated better with statistical significance, but there was no difference in visualization of the renal parenchyma or ureters. Use of iohexol in excretory urography may be advantageous in children who are at greatest risk for an adverse reaction to contrast media or in those most likely to benefit from use of a low osmolality contrast agent. 相似文献
14.
组织工程细胞支架的免疫原性研究 总被引:1,自引:1,他引:1
目的:以组织工程血管脱细胞支架和仿生髓核组织工程细胞支架、周围神经去细胞神经基膜管为例,介绍组织工程脱细胞支架的免疫原性研究情况.
方法:应用计算机检索Medline 1997-01/2007-03关于免疫原性的文章.检索词“Immunotoxicology”并限定文章的语种类为English.同时利用计算机检索中国期刊全文数据库1997-01/2007-03的相关文章,限定文章语言种类为中文,检索词“组织工程,免疫原性”.
结果:主要组织相容性复合体Ⅰ免疫组织化学方法能够检测血管脱细胞支架的免疫原性;组织学观察及反转录-聚合酶链反应检测γ-干扰素、白细胞介素2、白细胞介素4、白细胞介素10 mRNA表达,可以反映仿生髓核组织工程支架的免疫原性;主要组织相容性复合体Ⅱ抗原可以反映出经过化学萃取后的去细胞预变性神经基膜血管结构保留较完整,免疫原性低.
结论:脱细胞可以极大地降低组织工程支架的免疫原性,从而使得组织工程产品有更广阔的使用前景. 相似文献
15.
JJ Korelitz ; AE Williams ; MP Busch ; TF Zuck ; HE Ownby ; LJ Matijas ; DJ Wright 《Transfusion》1994,34(10):870-876
BACKGROUND: Most blood centers utilize a confidential unit exclusion (CUE) process, intended to reduce the risk of transfusion-associated infectious diseases by allowing high-risk donors confidentially to exclude their blood from use for transfusion. The effectiveness of this method remains controversial. STUDY DESIGN AND METHODS: Confirmatory or supplemental test results for antibodies to human immunodeficiency virus, human T-lymphotropic virus type I, and hepatitis C virus, as well as hepatitis B surface antigen and syphilis and screening test results for antibodies to hepatitis B core (antigen) and alanine aminotransferase levels were obtained for approximately 1.8 million units donated during 1991 and 1992 at five blood centers within the United States. The prevalences of these infectious disease markers in units that the donors confidentially excluded (CUE+) and units that the donors did not exclude (CUE-) were calculated and examined within demographic subgroups. RESULTS: Units that were CUE+ were 8 to 41 times more likely to be seropositive for antibodies to human immunodeficiency virus and hepatitis C virus, hepatitis B surface antigen, and syphilis and three to four times more likely to react for antibody to hepatitis B core (antigen) or to have elevated alanine aminotransferase levels than units that were CUE- (p < 0.001). The positive predictive value of CUE (the percentage of CUE+ units that were confirmed seropositive for any marker) was 3.5 percent, and the sensitivity of CUE (the percentage of confirmed-seropositive units that were CUE+) was 2.3 percent. CONCLUSION: The current CUE process has low sensitivity and apparently low positive predictive value, and in many cases, it appeared that donors misunderstood it. Yet, CUE was not a “random process,” as CUE+ units were more likely to be seropositive for any infectious disease marker than CUE- units. This suggests that efforts to improve the CUE system may be warranted. As risk factors for transfusion-transmitted infection become more difficult to identify by history-based screening, however, such efforts may have limited effect. 相似文献
16.
S Van der Borght V Janssens MF Schim van der Loeff A Kajemba H Rijckborst JMA Lange TF Rinke de Wit 《Bulletin of the World Health Organization》2009,87(10):794-798
Problem
A multinational company with operations in several African countries was committed to offer antiretroviral treatment to its employees and their dependants.Approach
The Accelerating Access Initiative (AAI), an initiative of six pharmaceutical companies and five United Nations’ agencies, offered the possibility of obtaining brand antiretroviral drugs (ARVs) at 10% of the commercial price. PharmAccess, a foundation aimed at removing barriers to AIDS treatment in Africa, helped to establish an HIV policy and treatment guidelines, and a workplace programme was rolled out from September 2001.Local setting
Private sector employers in Africa are keen to take more responsibility in HIV prevention and AIDS care. An important hurdle for African employers remains the price and availability of ARVs.Relevant changes
The programme encountered various hurdles, among them the need for multiple contracts with multiple companies, complex importation procedures, taxes levied on ARVs, lack of support from pharmaceutical companies in importation and transportation, slow delivery of the drugs, lack of institutional memory in pharmaceutical companies and government policies excluding the company from access to ARVs under the AAI.Lessons learned
The launch of the AAI enabled this multinational company to offer access to ARVs to its employees and dependants. The private sector should have access to these discounted drugs under the AAI. A network of local AAI offices should be created to assist in logistics of drugs ordering, purchase and clearance. No taxes should be levied on ARVs. 相似文献17.
To report our clinical experience on the use of oral erythromycin for the treatment of severe gastrointestinal dysmotility in preterm infants.
A case series study of seven preterm infants (six were very low birthweight) with severe intestinal dysmotility in a tertiary neonatal centre.
All responded favourably without adverse effects and tolerated full enteral feeding within 1–2 weeks of the commencement of the drug.
As prolonged total parenteral nutrition carries significant risk of complications, this therapy could be considered in selected preterm infants who fail to establish enteral feeding after an extended period, and in whom an anatomically obstructive lesion of the gastrointestinal tract has been excluded. Meanwhile, we would caution against the widespread implementation of this therapeutic approach until formal evaluation by randomized controlled trials have established the exact role of erythromycin, or its analogues, in the treatment of intestinal dysmotility in preterm infants. 相似文献
Methodology:
A case series study of seven preterm infants (six were very low birthweight) with severe intestinal dysmotility in a tertiary neonatal centre.
Results:
All responded favourably without adverse effects and tolerated full enteral feeding within 1–2 weeks of the commencement of the drug.
Conclusions:
As prolonged total parenteral nutrition carries significant risk of complications, this therapy could be considered in selected preterm infants who fail to establish enteral feeding after an extended period, and in whom an anatomically obstructive lesion of the gastrointestinal tract has been excluded. Meanwhile, we would caution against the widespread implementation of this therapeutic approach until formal evaluation by randomized controlled trials have established the exact role of erythromycin, or its analogues, in the treatment of intestinal dysmotility in preterm infants. 相似文献
18.
Kirsten M van Steenbergen-Weijenburg Lars de Vroege Robert R Ploeger Jan W Brals Martijn G Vloedbeld Thiemo F Veneman Leona Hakkaart-van Roijen Frans FH Rutten Aartjan TF Beekman Christina M van der Feltz-Cornelis 《BMC health services research》2010,10(1):235
Background
For the treatment of depression in diabetes patients, it is important that depression is recognized at an early stage. A screening method for depression is the patient health questionnaire (PHQ-9). The aim of this study is to validate the 9-item Patient Health Questionnaire (PHQ-9) as a screening instrument for depression in diabetes patients in outpatient clinics. 相似文献19.
Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping
Patrick TF. Kennedy Natalie Phillips Jaya Chandrasekhar Ruth Jacobs Michael Jacobs Geoffrey Dusheiko 《Liver international》2008,28(5):699-704
Background: Current oral therapy for hepatitis B virus (HBV) is limited by the presence of resistance leading to resumption of higher levels of HBV replication. Therefore, there is a need for a better definition of the potential role and limitations of lamivudine or similar therapies, used alone. Aims: To examine the viability of lamivudine and similar monotherapies as a treatment strategy in chronic HBV in the face of the worldwide burden of disease. Methods: We have reviewed the role of lamivudine monotherapy in the treatment of chronic HBV in a single tertiary referral liver centre over a 9‐year period. We analysed the outcome in 90 patients where lamivudine has apparently conferred long‐term viral suppression and investigated the development of genotypic resistance in the absence of ostensible phenotypic resistance. Patients were subdivided into hepatitis B e antigen (HBeAg)‐positive and anti‐HBe‐positive groups. Results: Virtually all HBeAg‐positive patients who failed to seroconvert have progressed to combination antiviral therapy. Only 19%(7/36) of HBeAg‐negative patients have continued suppression without detectable genotypic change after 4 years of therapy. Conclusions: These data demonstrate that despite a relatively low level of viraemia in HBeAg‐negative patients, we could detect resistance mutations by direct sequencing in all patients with amplifiable HBV DNA. Our results suggest that for patients with ongoing replication at ‘amplifiable’ levels of HBV DNA, but <105 copies/ml, genotypic selection is readily detectable. Lamivudine monotherapy has not sufficed for the overwhelming majority of patients. 相似文献
20.